Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
dRx Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
dRx Capital

dRx Capital

Operating

dRx Capital: Novartis' digital health venture fund, investing in tech transforming healthcare & optimizing pharma practices.

Location
Basel, Basel-Stadt, CH
Founded
2015
Firm
Compare
Portfolio
Employees
Website

dRx Capital, founded in 2015, is Novartis' Digital Health Venture Fund focused on investing in entrepreneurs who are transforming healthcare through data and digital technology. The firm targets technology platforms that enhance access to healthcare and reimagine medical practices, with a particular emphasis on AI & ML, big data, R&D optimization, patient care, and the pharma supply chain. dRx Capital typically invests in Series A, B, and C rounds, with occasional pre-seed and post-IPO equity investments.

Notable portfolio companies include Freenome, H1, Pear Therapeutics, and Omada Health. The firm is led by key decision-makers affiliated with Novartis, leveraging their extensive expertise in the pharmaceutical industry. dRx Capital's investment philosophy centers on driving operational efficiency and transforming current healthcare practices. They offer unique value-add services such as strategic guidance and access to Novartis' vast resources and networks, providing significant support to their portfolio companies.

dRx Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments20
Current Portfolio Count14
Total Portfolio Exits0

Top Investment Stages

Series B9 (45.0%)
Series C7 (35.0%)
Series A2 (10.0%)
Post Ipo Equity1 (5.0%)
Pre-Seed1 (5.0%)

Stage Mix

Series B 45%Series C 35%Series A 10%Post Ipo Equity 5%Pre-Seed 5%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Koneksa Health logo

Koneksa Health

Pear Therapeutics logo

Pear Therapeutics

H1 logo

H1

Flywheel logo

Flywheel

Aspen RxHealth logo

Aspen RxHealth

Vineti logo

Vineti

RxVantage logo

RxVantage

Freenome logo

Freenome

Xealth logo

Xealth

Cala Health logo

Cala Health

Aktana logo

Aktana

Mekonos logo

Mekonos

Cota Healthcare logo

Cota Healthcare

Omada Health logo

Omada Health

dRx Capital - Similar Investment Firms

Novartis Venture Fund logo

Novartis Venture Fund

nvfund.com

FundRx logo

FundRx

mbxcapital.com

Drads Capital logo

Drads Capital

dradscapital.com

DigitalDx Ventures logo

DigitalDx Ventures

digitaldx.com

DigiTx Partners logo

DigiTx Partners

digitx.com

Digitalis Ventures logo

Digitalis Ventures

Draper Associates logo

Draper Associates

draper.vc

Distributed Ventures logo

Distributed Ventures

distributedvc.com

NextGen Ventures logo

NextGen Ventures

nextgenventures.nl

Aldrich Capital Partners logo

Aldrich Capital Partners

aldrichcap.com

HealthTrend Capital logo

HealthTrend Capital

healthtrendcap.com

DaVita Venture Group logo

DaVita Venture Group

Lrvhealth logo

Lrvhealth

lrvhealth.com

Ambit Health Ventures logo

Ambit Health Ventures

HealthX Management logo

HealthX Management

dRx Capital - Classification

Also Known As
  • DRX Capital Limited
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified